Literature DB >> 18305406

Anti-tumor immunostimulatory effect of heat-killed tumor cells.

Taek Joon Yoon1, Ji Yeon Kim, Hyojeong Kim, Changwan Hong, Hyunji Lee, Chang Kwon Lee, Kwang Ho Lee, Seokmann Hong, Se Ho Park.   

Abstract

As a part of our ongoing search for a safe and efficient anti-tumor vaccine, we attempted to determine whether the molecular nature of certain tumor antigens would influence immune responses against tumor cells. As compared with freeze-thawed or formaldehyde-fixed tumor antigens, heat-denatured tumor antigens elicited profound anti-tumor immune responses and greatly inhibited the growth of live tumor cells. The heat-denatured tumor antigens induced a substantial increase in the anti-tumor CTL response in the absence of any adjuvant material. This response appears to be initiated by strong activation of the antigen-presenting cells, which may recognize heat-denatured protein antigens. Upon recognition of the heat-denatured tumor antigens, macrophages and dendritic cells were found to acutely upregulate the expression of co-stimulatory molecules such as B7.2, as well as the secretion of inflammatory cytokines such as IL-12 and TNF-alpha. The results of this study indicate that heat-denatured tumor extracts might elicit protective anti-tumor adaptive immune responses and also raise the possibility that a safe and efficient adjuvant-free tumor vaccine might be developed in conjunction with a dendritic cell-based tumor vaccine.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18305406      PMCID: PMC2679326          DOI: 10.3858/emm.2008.40.1.130

Source DB:  PubMed          Journal:  Exp Mol Med        ISSN: 1226-3613            Impact factor:   8.718


  43 in total

1.  Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses.

Authors:  Seung-Yong Seong; Polly Matzinger
Journal:  Nat Rev Immunol       Date:  2004-06       Impact factor: 53.106

Review 2.  Toll-like receptor control of the adaptive immune responses.

Authors:  Akiko Iwasaki; Ruslan Medzhitov
Journal:  Nat Immunol       Date:  2004-10       Impact factor: 25.606

3.  The JAM test. A simple assay for DNA fragmentation and cell death.

Authors:  P Matzinger
Journal:  J Immunol Methods       Date:  1991-12-15       Impact factor: 2.303

4.  Association of tapasin and HLA class I antigen down-regulation in primary maxillary sinus squamous cell carcinoma lesions with reduced survival of patients.

Authors:  Takeshi Ogino; Nobuyuki Bandoh; Tatsuya Hayashi; Naoyuki Miyokawa; Yasuaki Harabuchi; Soldano Ferrone
Journal:  Clin Cancer Res       Date:  2003-09-15       Impact factor: 12.531

5.  A tumor-associated glycoprotein that blocks MHC class II-dependent antigen presentation by dendritic cells.

Authors:  Ralf Gutzmer; Wei Li; Shaheen Sutterwala; Maria P Lemos; J Ignasi Elizalde; Sandra L Urtishak; Edward M Behrens; Patricia M Rivers; Katia Schlienger; Terri M Laufer; Stephen L Eck; Michael S Marks
Journal:  J Immunol       Date:  2004-07-15       Impact factor: 5.422

Review 6.  Dendritic cell-tumor fusion vaccines for renal cell carcinoma.

Authors:  David Avigan
Journal:  Clin Cancer Res       Date:  2004-09-15       Impact factor: 12.531

Review 7.  Escape from immunotherapy: possible mechanisms that influence tumor regression/progression.

Authors:  Murrium Ahmad; Robert C Rees; Selman A Ali
Journal:  Cancer Immunol Immunother       Date:  2004-06-10       Impact factor: 6.968

Review 8.  Dendritic cells as vectors for immunotherapy of cancer.

Authors:  Sophie Paczesny; Hideki Ueno; Joseph Fay; Jacques Banchereau; A Karolina Palucka
Journal:  Semin Cancer Biol       Date:  2003-12       Impact factor: 15.707

9.  Cancer immunotherapy: moving beyond current vaccines.

Authors:  Steven A Rosenberg; James C Yang; Nicholas P Restifo
Journal:  Nat Med       Date:  2004-09       Impact factor: 53.440

10.  Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens.

Authors:  Alex Cuenca; Fengdong Cheng; Hongwei Wang; Jason Brayer; Pedro Horna; Lingping Gu; Harold Bien; Ivan M Borrello; Hyam I Levitsky; Eduardo M Sotomayor
Journal:  Cancer Res       Date:  2003-12-15       Impact factor: 12.701

View more
  9 in total

Review 1.  InCVAX--a novel strategy for treatment of late-stage, metastatic cancers through photoimmunotherapy induced tumor-specific immunity.

Authors:  Feifan Zhou; Xiaosong Li; Mark F Naylor; Tomas Hode; Robert E Nordquist; Luciano Alleruzzo; Joseph Raker; Samuel S K Lam; Nan Du; Lei Shi; Xiuli Wang; Wei R Chen
Journal:  Cancer Lett       Date:  2015-01-26       Impact factor: 8.679

Review 2.  Immunogenicity of necrotic cell death.

Authors:  Jaba Gamrekelashvili; Tim F Greten; Firouzeh Korangy
Journal:  Cell Mol Life Sci       Date:  2014-10-02       Impact factor: 9.261

3.  Local hyperthermia treatment of tumors induces CD8(+) T cell-mediated resistance against distal and secondary tumors.

Authors:  Seiko Toraya-Brown; Mee Rie Sheen; Peisheng Zhang; Lei Chen; Jason R Baird; Eugene Demidenko; Mary Jo Turk; P Jack Hoopes; Jose R Conejo-Garcia; Steven Fiering
Journal:  Nanomedicine       Date:  2014-02-22       Impact factor: 5.307

4.  Vaccination with Human Induced Pluripotent Stem Cells Creates an Antigen-Specific Immune Response Against HIV-1 gp160.

Authors:  Shinji Yoshizaki; Mayuko Nishi; Asami Kondo; Yoshitsugu Kojima; Naoki Yamamoto; Akihide Ryo
Journal:  Front Microbiol       Date:  2011-02-22       Impact factor: 5.640

5.  Dendritic cells as danger-recognizing biosensors.

Authors:  Mia Gi; Wooseok Im; Seokmann Hong
Journal:  Sensors (Basel)       Date:  2009-08-27       Impact factor: 3.576

Review 6.  Dendritic cell-based vaccination in cancer: therapeutic implications emerging from murine models.

Authors:  Soledad Mac Keon; María Sol Ruiz; Silvina Gazzaniga; Rosa Wainstok
Journal:  Front Immunol       Date:  2015-05-20       Impact factor: 7.561

7.  Enhanced T Cell Responses Induced by a Necrotic Dendritic Cell Vaccine, Expressing HCV NS3.

Authors:  Zelalem A Mekonnen; Makutiro G Masavuli; Wenbo Yu; Jason Gummow; Dawn M Whelan; Zahraa Al-Delfi; Joseph Torresi; Eric J Gowans; Branka Grubor-Bauk
Journal:  Front Microbiol       Date:  2020-11-24       Impact factor: 5.640

8.  RNA polymerase II pausing factor NELF in CD8+ T cells promotes antitumor immunity.

Authors:  Bogang Wu; Xiaowen Zhang; Huai-Chin Chiang; Haihui Pan; Bin Yuan; Payal Mitra; Leilei Qi; Hayk Simonyan; Colin N Young; Eric Yvon; Yanfen Hu; Nu Zhang; Rong Li
Journal:  Nat Commun       Date:  2022-04-20       Impact factor: 17.694

Review 9.  Chitin, chitosan, and glycated chitosan regulate immune responses: the novel adjuvants for cancer vaccine.

Authors:  Xiaosong Li; Min Min; Nan Du; Ying Gu; Tomas Hode; Mark Naylor; Dianjun Chen; Robert E Nordquist; Wei R Chen
Journal:  Clin Dev Immunol       Date:  2013-03-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.